- News & Media
Tikcro Technologies Ltd., powered by a novel 3D antigen design technology, generates new antibodies that block receptor/ligand surface domains of immune modulators and re-activate the body’s immune system to fight cancer. Our antibodies are in various pre-clinical stages.
Following extensive collaborative research with the Weizmann Institute of Science in Israel, we are developing drug-candidates by leveraging a unique antigen design technology for the generation of new functional blocking antibodies. This approach has shown early success with pipeline below. Going forward, in 2017-2018 we plan to advance with early-stage candidates to rigorous pre-clinical trials and aim to build sufficient data for further progress and clinical trials.